Med. praxi. 2023;20(5):275-281 | DOI: 10.36290/med.2023.050

Modern therapy of chronic venous disease - what's new?

MUDr. Robert Vlachovský, Ph.D.1, MUDr. Jan Novák, Ph.D.2
1 II. chirurgická klinika, Centrum cévních onemocnění, FN u sv. Anny v Brně a Lékařská fakulta Masarykovy univerzity, Brno
2 II. interní klinika FN u sv. Anny v Brně a Lékařská fakulta Masarykovy univerzity, Brno

Chronic venous disease (CVD) is a civilization disease with increasing prevalence in the general population. It arises due to chronic venous wall inflammation and remodeling, resulting in venous hypertension. Clinical features of CVD are highly variable, and given its progressive nature, it is reasonable to initiate adequate treatment as soon as possible. The cornerstones of the best medical therapy for CVD include regimen measures, well-managed and long-term conservative treatment (compression, effective venoactive drugs), and, in indicated cases, surgical intervention. Significant changes have occurred in recent years in the approach to patients and to the treatment itself, especially in the field of intravenous surgery, the timing of conservative treatment initiation, or in the care of patients with active venous ulcers. Only through the joint efforts of physicians of different specialties and CVD patients, especially by educating and motivating them to follow the recommended treatment procedures, can we reduce the percentage of untreated patients, slow down disease progression, and achieve excellent results in the intervention treatment.

Keywords: varicose veins, chronic venous disease, varicose veins surgery, endovenous procedures, conservative treatment, venoactive drugs.

Received: October 13, 2023; Revised: October 24, 2023; Accepted: November 20, 2023; Published: December 19, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlachovský R, Novák J. Modern therapy of chronic venous disease - what's new? Med. praxi. 2023;20(5):275-281. doi: 10.36290/med.2023.050.
Download citation

References

  1. Karetová D, Chochola M, et al. Vaskulární medicína. Praha: Maxdorf; 2017.
  2. De Maessener M, Kakkos S, Aherne T, et al., European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the management of chronic venous disease of the lower limbs, Eur J Vasc Endovasc Surg. 2022 Feb;63(2):184-267. Go to original source... Go to PubMed...
  3. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I (chapters 1-8) Int Angiol. 2018 Jun;37(3):181-254. Go to original source... Go to PubMed...
  4. Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part II (chapters 9-18) Intern Angiol. 2020. 39(3):175-240. Go to original source... Go to PubMed...
  5. Karetová D, Roztočil K, Vlachovský R, et al. Léčba chronických žilních chorob 2023. Doporučený postup České angiologické společnosti ČLS JEP. 2023 Česká angiologická společnost České lékařské společnosti J. E. Purkyně.
  6. Vital A, Carles D, Serise JM, et al. Evidence for unmyelinated C fibers and inflammatory cells in human varicose saphenous. Int J Angiol. 2010;19:73-7. Go to original source... Go to PubMed...
  7. Karetová D, Bultas J. Chronická žilní nemoc a kardiovaskulární onemocnění. Med. praxi.2023;20(1):17-24. Go to original source...
  8. Vojtíšková J. Czech Vein Program - výsledky epidemiologického programu. Praktická flebologie. 2012;1:8-13.
  9. Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342-52. Go to original source... Go to PubMed...
  10. Navrátilová Z. Léčba příznaků a projevů chronické žilní insuficience dolních končetin. Dermatol. Praxi. 2015;9(4):157-61.
  11. Černohorská J. Chronické žilní onemocnění - napínavá detektivka pro lékaře, pacienty i farmaceuty. Prakt. lékáren. 2016;12(2):54-7. Go to original source...
  12. Rother U, Grussler A, Griesbach C, et al. Safety of medical compression stockings in patients with diabetes mellitus or peripheral arterial disease. BMJ Open Diabetes Res Care. 2020 Jun;8(1):e001316. Go to original source... Go to PubMed...
  13. Tsoukanov YT, Tsoukanov AY, Nikolaychuk A. Great saphenous vein transitory reflux in patients with symptoms related to chronic venous disorders but without visible signs (C0s), and its correction with MPFF treatment. Phlebolymphology. 2015;22(1):18-24. Go to original source...
  14. Hirmerová J. Farmakologická terapie symptomů chronické žilní insuficience dolních končetin. Interní Med. 2018;20(5):227-32. Go to original source...
  15. Slonková V. Nová klasifikace venoaktivních léků. Dermatol. Praxi. 2016;10(4):178-80. Go to original source...
  16. Lenkovic M, Stanic­‑Zgombic Z, Manestar­‑Blazic T, et al. Benefit of Daflon 500 mg in the reduction of chronic venous disease­‑related symptoms. Phlebolyphology. 2012;19(2):79-83.
  17. Allaert FA. Meta­‑analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012 Aug;31(4):310-5.
  18. Paysant J, Sansilvestri­‑Morel P, Bouskela E, et al. Different flavonoids present in the micronized purified flavonoid fiction (Daflon 500 mg) contribute to its anti­‑hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol. 2008 Feb;27(1):81-5.
  19. Monjotin N, Tenca G. Lymphotonic activity of Ruscus extract, hesperidin methyl chalcone and vitamin C in human lymphatic smooth muscle cells. Microvasc Res. 2022 Jan;139:104274. Go to original source... Go to PubMed...
  20. Gohel MS, Barwell JR, Taylor M, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ. 2007;335 (7610):83. Go to original source... Go to PubMed...
  21. Roztočil K, Štvrtinová V, Strejček J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol. 2003 Mar;22(1):24-31.
  22. Coleridge­‑Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta­‑analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J. Vasc Endovasc Surg. 2005;30:198-208. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.